0001654954-23-002947.txt : 20230315 0001654954-23-002947.hdr.sgml : 20230315 20230315165659 ACCESSION NUMBER: 0001654954-23-002947 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20230315 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230315 DATE AS OF CHANGE: 20230315 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Zomedica Corp. CENTRAL INDEX KEY: 0001684144 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38298 FILM NUMBER: 23735964 BUSINESS ADDRESS: STREET 1: 100 PHOENIX DRIVE STREET 2: SUITE 125 CITY: ANN ARBOR STATE: MI ZIP: 48108 BUSINESS PHONE: (734) 369-2555 MAIL ADDRESS: STREET 1: 100 PHOENIX DRIVE STREET 2: SUITE 125 CITY: ANN ARBOR STATE: MI ZIP: 48108 FORMER COMPANY: FORMER CONFORMED NAME: Zomedica Pharmaceuticals Corp. DATE OF NAME CHANGE: 20160908 8-K 1 zom_8k.htm FORM 8-K zom_8k.htm

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): March 15, 2023

 

ZOMEDICA CORP.

(Exact name of registrant as specified in its charter)

 

Alberta, Canada

 

001-38298

 

N/A

(State or other jurisdiction

 

(Commission

 

(IRS Employer

of incorporation)

 

File Number)

 

Identification No.)

 

100 Phoenix Drive, Suite 125, Ann Arbor, Michigan

 

48108

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code: (734) 369-2555

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Shares, without par value

ZOM

NYSE American

 

 

 

 

Item 2.02 Results of Operations and Financial Condition.

 

On March 15, 2023, Zomedica Corp. (the “Company”) issued a press release announcing the Company’s financial results for the year ended December 31, 2023. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated by reference herein.

 

The information in this Item 2.02, and Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this current report shall not be incorporated by reference into any registration statement or other document filed with the Securities and Exchange Commission, whether filed before or after the date hereof regardless of any general incorporation language in any such filing, unless we expressly set forth in such filing that such information is to be considered “filed” or incorporated by reference therein.

 

Item 9.01 Exhibits.

 

(d) Exhibits

 

 

99.1

 

Press Release, dated March 15, 2023.

 

 

 

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 
-2-

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

                                                                                            

 

ZOMEDICA CORP.

 

 

 

 

 

Date: March 15, 2023

By:

/s/ Ann Marie Cotter

 

 

Name:

Ann Marie Cotter

 

 

Title:

Chief Financial Officer

 

                                                    

 

 
-3-

 

 

Exhibit Index

 

99.1 

 

Press Release, dated March 15, 2023.

 

 

 

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 
-4-

 

 EX-99.1 2 zom_ex991.htm PRESS RELEASE zom_ex991.htm

EXHIBIT 99.1

 

Zomedica Corporation Reports 2022 Results: $18.9 Million Revenue; 72% Gross Margin & $156 Million in Liquidity

Revenue up 361% from 2021 through combination of acquisitions and organic growth

 

ANN ARBOR, MI / ACCESSWIRE / March 15, 2023 / Zomedica Corp. (NYSE American:ZOM) (“Zomedica” or the “Company”), a veterinary health company offering point-of-care diagnostics and therapeutic products for companion animals, today reported consolidated financial results for the year ended December 31, 2022. Amounts, unless specified otherwise, are expressed in U.S. dollars and presented under accounting principles generally accepted in the United States of America (“U.S. GAAP”).

 

Larry Heaton, Zomedica’s Chief Executive Officer, commented: “ At Zomedica we’re bringing products to Veterinarians to help them do the things they really LOVE to do – improve the quality of care for the pets and the satisfaction of the pet parents; and to help them do the things they really NEED to do – improve workflow, cashflow and profitability.

 

“2022 was another transformational year for Zomedica through acquisitions of products that meet this standard, along with significant improvements in infrastructure, manufacturing capacity, and commercial capabilities. Through these acquisitions and our internal efforts, we have:

 

 

-

expanded our product portfolio to include five product platforms;

 

-

acquired and expanded robust marketing and social media programs;

 

-

developed the commercial team to include professionally led field sales, inside sales, and professional services veterinarians;

 

-

acquired and expanded relationships with domestic animal health distributors and online retailers;

 

-

acquired and expanded a robust set of international subsidiary and distribution channels;

 

-

built manufacturing and distribution capability and capacity at our new Global Manufacturing & Distribution Center in Roswell, Georgia;

 

-

grown revenue from $0 in 2020 to $4.1 million in 2021 to $18.9 million in 2022; and

 

-

established a pipeline of new product launches for 2023.

 

“During the year, we launched two new TRUFORMA® Assays (ACTH and fT4), both providing the only assay of their type available at the point of care. In 2023, we entered into new license and transition services agreements with our TRUFORMA development partner giving us the opportunity to develop and manufacture assays and instruments ourselves. We are planning to continue our investment in the development of additional assays which we believe will increase the utility of the TRUFORMA platform for our customers over time. For 2023 these include planned assays for non-infectious gastrointestinal disease and our first assays for horses, both of which we expect to launch in 2023.

 

“Our PulseVet® platform continues to perform strongly. While historically used in the treatment of horses, the 2022 introduction of the X-trode handpiece, which enables use with small animals without sedation, is now being marketed to small animal veterinarians. In fact, small animal device sales grew 405% in 2022, from 21 devices in 2022 to 106 devices in 2022.

 

“Our Assisi Loop® line of products, which joined Zomedica’s portfolio of offerings in Q3, proved to be a solid contributor to our 2022 results with roughly $2.1M in sales for the year. As we leverage our communication and marketing networks, we expect Assisi recognition and brand awareness to increase, resulting in expected growth in 2023.

 

 
1

 

 

“Overall, we are pleased with our progress in 2022 and are excited to continue building on this traction and growth trajectory as we introduce two new product platforms into the market in 2023. In early January we launched the VetGuardian® zero-touch vital signs remote monitoring system. During the second quarter we expect to launch our new TRUVIEWTM digital microscope which features automatic slide preparation to improve both workflow and image quality.

 

“Additionally, we continue to evaluate strategic business development and M&A opportunities to further bolster our overall growth opportunity in the large and growing animal health sector. We believe we are well positioned to continue the momentum in 2023 and beyond.”

 

Fourth Quarter Financial Highlights

 

 

·

Revenue for the fourth quarter of 2022 was $6.2 million, an increase of 51% compared to the fourth quarter of 2021, primarily driven by:

 

 

○

 an increase in PulseVet® sales, which grew 23% over the prior year quarter to 4.9 million; and

 

 

○

 the inclusion of sales of the recently acquired Assisi® products of $1.1 million

 

 

 

 

 

·

Gross margin was 70% for the fourth quarter of 2022

 

 

 

 

 

·

Cash burn during the fourth quarter was $2.5 million.

 

Full Year 2022 Financial Highlights

 

 

·

 Revenue for 2022 was $18.9 million, an increase of 361% compared to 2021, primarily driven by a full year of PulseVet sales and the inclusion of the recently acquired Assisi products. When including pre-acquisition sales of PulseVet and Assisi products, Zomedica 2022 revenue was up 25% over 2021 combined revenues.

 

 

 

 

·

 Gross Margin was 72% for the full year 2022.

 

 

 

 

·

 Cash, Cash Equivalents, and Available-for-Sale Securities were approximately $156 million as of December 31, 2022.

 

 

 

 

·

 Zomedica has had no cash on deposit with either Silicon Valley Bank or Signature Bank.

 

Summary Year End 2022 Results

 

Revenue for the year ended December 31, 2022 was $18.9 million, compared to $4.1 million for the year ended December 31, 2021, an increase of $14.8 million or 361%. The increase was primarily due to the inclusion of a full year of our PulseVet platform and our recently acquired Assisi products which had combined revenues of $18.5 million consisting of consumables, instruments, trodes, and warranty services sold worldwide. Revenues from sales of cartridges from our TRUFORMA® platform were $0.4 million compared to $0.1 million, an increase of $0.3 million or 300%.

 

 
2

 

 

Cost of revenue for the year ended December 31, 2022 was $5.3 million, compared to $1.1 million for the year ended December 31, 2021, an increase of $4.2 million or 382%. Cost of revenue primarily resulted from costs associated with sales of our PulseVet platform and Assisi products which totaled $5.0 million, as well as $0.3 million from costs associated with sales of our TRUFORMA® platform.

 

Gross profit margin for the year ended December 31, 2022 was $13.7 million or 72%, compared to $3.1 million or 74% for the year ended December 31, 2021, an increase of $10.6 million.

 

Research and development expense for the year ended December 31, 2022 was $2.6 million, compared to $1.7 million for the year ended December 31, 2021, an increase of $0.9 million or 53%. The increase was primarily driven by an increase in contracted expenses for research fees and trials as we continue to develop and test our next generation of TRUFORMA assays.

 

Selling, general, and administrative expense for the year ended December 31, 2022 was $33.0 million, compared to $22.8 million for the year ended December 31, 2021, an increase of $10.2 million or 45%. The increase was primarily driven by salaries and (noncash) stock option expense associated with increased hiring campaigns, the inclusion of PulseVet, Revo Squared and Assisi headcount, acquisition related intangible amortization, increases in office expense, travel and tradeshow attendance/sponsorships associated with a lifting of COVID restrictions, our introduction of new TRUFORMA® assays, and marketing of our new product lines.

 

Our net loss for the year ended December 31, 2022 was $17.0 million, compared to a loss of $18.4 million for the year ended December 31, 2021, a decrease of $1.4 million or 8%.

 

Liquidity and Outstanding Share Capital

 

Zomedica had cash, cash equivalents, and available-for-sale securities of approximately $156.0 million as of December 31, 2022, compared to approximately $195.0 million as of December 31, 2021. The decrease in cash during the year ended December 31, 2022, is mainly a result of cash flows used in operating and investing activities as discussed below.

 

Net cash used in operating activities for the year ended December 31, 2022 was $11.7 million, compared to $14.3 million for the year ended December 31, 2021, a decrease in cash used of $2.6 million or 18%. The decrease in cash used in operations primarily resulted from an increase in non-cash expenses including stock-based compensation expense, depreciation and amortization, and volume/headcount related accruals for unbilled inventory, salaries and wages, and sales and use tax.

 

Net cash used in investing activities for the year ended December 31, 2022 was $155.9 million, compared to $71.9 million for the year ended December 31, 2021, an increase of $84.0 million or 117%. The increase in cash used in investing activities primarily resulted from significant investments in available for sale securities, our acquisitions of Assisi and Revo Squared, leasehold improvements, and expenditures to improve our ecommerce, internal sales, and accounting programs.

 

Net cash provided by financing activities for the year ended December 31, 2022 was $0 compared to $219.2 million for the year ended December 31, 2021, a decrease of 100%. Cash provided by financing activities in 2021 primarily resulted from proceeds from the February 2021 public offering of our common shares, partially offset by stock issuance costs.

 

At December 31, 2022, Zomedica had 979,949,668 common shares issued and outstanding.

 

 
3

 

 

For complete financial results, please see Zomedica’s filings on EDGAR and SEDAR or visit the Zomedica website at www.ZOMEDICA.com.

 

About Zomedica

 

Based in Ann Arbor, Michigan, Zomedica (NYSE American:ZOM) is a veterinary health company creating products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. Zomedica’s product portfolio includes innovative diagnostics and medical devices that emphasize patient health and practice health. Zomedica’s mission is to provide veterinarians the opportunity to increase productivity and grow revenue while better serving the animals in their care. For more information, visit www.zomedica.com.

 

Follow Zomedica

 

 

·

 Email Alerts: http://investors.zomedica.com

 

·

 LinkedIn: https://www.linkedin.com/company/zomedica

 

·

 Facebook: https://m.facebook.com/zomedica

 

·

 Twitter: https://twitter.com/zomedica

 

·

 Instagram: https://www.instagram.com/zomedica_inc

 

Reader Advisory

 

Except for statements of historical fact, this news release contains certain “forward-looking information” or “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate” and other similar words, or statements that certain events or conditions “may” or “will” occur and include statements relating to our expectations regarding future results. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance, or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.

 

Forward-looking information is based on the opinions and estimates of management at the date the statements are made, including assumptions with respect to economic growth, demand for the Company’s products, the Company’s ability to produce and sell its products, sufficiency of our budgeted capital and operating expenditures, the satisfaction by our strategic partners of their obligations under our commercial agreements, our ability to realize upon our business plans and cost control efforts and the impact of COVID-19 on our business, results and financial condition.

 

 
4

 

 

Our forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: the finalization of the accounting procedures necessary to report our financial results for 2022, the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments, uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts, as well as the cost of commercialization efforts, including the cost to develop an internal sales force and manage our growth; uncertainty as to our ability to successfully integrate acquisitions; uncertainty as to our ability to supply products in response to customer demand; uncertainty as to the likelihood and timing of any required regulatory approvals, and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our commercial agreements, including product manufacturing obligations; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, risks related to the COVID-19 pandemic and its impact upon our business operations generally, including our ability to develop and commercialize our products, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR at www.sedar.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive.

 

The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.

 

Investor Relations Contacts:

 

Dave Gentry

RedChip Companies Inc.

1-800-RED-CHIP (733-2447)

Or 407-491-4498

ZOM@redchip.com

 

SOURCE: Zomedica Corp.

 

 
5

 

 EX-101.SCH 3 zom-20230315.xsd XBRL TAXONOMY EXTENSION SCHEMA 000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 zom-20230315_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Entity Registrant Name Entity Central Index Key Document Type Amendment Flag Entity Emerging Growth Company Document Period End Date Entity File Number Entity Address Address Line 1 Entity Address Address Line 2 Entity Address City Or Town Entity Address State Or Province Entity Address Country Entity Address Postal Zip Code City Area Code Written Communications Soliciting Material Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Local Phone Number Security 12b Title Trading Symbol Security Exchange Name EX-101.CAL 5 zom-20230315_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.PRE 6 zom-20230315_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EX-101.DEF 7 zom-20230315_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE XML 8 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Cover
Mar. 15, 2023
Cover [Abstract]  
Entity Registrant Name ZOMEDICA CORP.
Entity Central Index Key 0001684144
Document Type 8-K
Amendment Flag false
Entity Emerging Growth Company false
Document Period End Date Mar. 15, 2023
Entity File Number 001-38298
Entity Address Address Line 1 100 Phoenix Drive
Entity Address Address Line 2 Suite 125
Entity Address City Or Town Ann Arbor
Entity Address State Or Province MI
Entity Address Country CA
Entity Address Postal Zip Code 48108
City Area Code 734
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Local Phone Number 369-2555
Security 12b Title Common Shares, without par value
Trading Symbol ZOM
Security Exchange Name NYSE
XML 9 zom_8k_htm.xml IDEA: XBRL DOCUMENT 0001684144 2023-03-15 2023-03-15 iso4217:USD shares iso4217:USD shares 0001684144 false 8-K 2023-03-15 ZOMEDICA CORP. CA 001-38298 100 Phoenix Drive Suite 125 Ann Arbor MI 48108 734 369-2555 false false false false false Common Shares, without par value ZOM NYSE EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 1 22 1 false 0 0 false 3 false false R1.htm 000001 - Document - Cover Sheet http://zomedica.com/role/Cover Cover Cover 1 false false All Reports Book All Reports [dq-0547-EntityIncorporationStateCountryCode-Missing] Submission type 8-K should have a non-empty value for EntityIncorporationStateCountryCode in the Required Context. zom_8k.htm [dq-0547-EntityTaxIdentificationNumber-Missing] Submission type 8-K should have a non-empty value for EntityTaxIdentificationNumber in the Required Context. zom_8k.htm zom_8k.htm zom-20230315.xsd zom-20230315_cal.xml zom-20230315_def.xml zom-20230315_lab.xml zom-20230315_pre.xml zom_ex991.htm http://xbrl.sec.gov/dei/2022 true true JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "zom_8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 22 }, "contextCount": 1, "dts": { "calculationLink": { "local": [ "zom-20230315_cal.xml" ] }, "definitionLink": { "local": [ "zom-20230315_def.xml" ] }, "inline": { "local": [ "zom_8k.htm" ] }, "labelLink": { "local": [ "zom-20230315_lab.xml" ] }, "presentationLink": { "local": [ "zom-20230315_pre.xml" ] }, "schema": { "local": [ "zom-20230315.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/currency/2022/currency-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/exch/2022/exch-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd", "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "zom", "nsuri": "http://zomedica.com/20230315", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "strong", "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "zom_8k.htm", "contextRef": "From2023-03-15to2023-03-15", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://zomedica.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "strong", "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "zom_8k.htm", "contextRef": "From2023-03-15to2023-03-15", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zomedica.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zomedica.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zomedica.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zomedica.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line 1" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zomedica.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line 2" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zomedica.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zomedica.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zomedica.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zomedica.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zomedica.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zomedica.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zomedica.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zomedica.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zomedica.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zomedica.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zomedica.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zomedica.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zomedica.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zomedica.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zomedica.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zomedica.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zomedica.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 17 0001654954-23-002947-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001654954-23-002947-xbrl.zip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end